Table 2 Adjusted Odds Ratio for Risk of ACS According to Five Selected Plasma Cytokines in Two Case-control Validation Sets.
Cytokines | Validation Set 1 | Validation Set 2 | Pooled analysis of the two validation sets | |||
---|---|---|---|---|---|---|
Adjusted OR (95% CI) | P | Adjusted OR (95% CI) | P | Adjusted OR (95% CI) | P | |
Osteopontin | ||||||
  Model 1 | 4.65 (2.49–8.67) | <0.001 | 3.86 (2.39–6.22) | <0.001 | 4.12 (2.81–6.04) | <0.001 |
  Model 2 | 4.68 (2.48–8.85) | <0.001 | 3.64 (2.24–5.90) | <0.001 | 4.04 (2.74–5.95) | <0.001 |
  Model 3 | 3.89 (1.56–5.47) | 0.023 | 5.98 (3.43–10.44) | <0.001 | 4.64 (3.16–6.79) | <0.001 |
CCL23 | ||||||
  Model 1 | 2.57 (1.57–4.22) | <0.001 | 9.64 (4.46–20.83) | <0.001 | 4.70 (1.38–15.97) | 0.013 |
  Model 2 | 2.54 (1.55–4.17) | <0.001 | 8.80 (4.12–18.81) | <0.001 | 4.11 (2.76–6.10) | 0.009 |
  Model 3 | 3.01 (1.51–5.99) | 0.002 | 4.37 (2.56–7.46) | <0.001 | 3.60 (2.45–5.28) | <0.001 |
BDNF | ||||||
  Model 1 | 0.53 (0.41–0.69) | <0.001 | 0.55 (0.41–0.74) | <0.001 | 0.54 (0.44–0.66) | <0.001 |
  Model 2 | 0.51 (0.39–0.67) | <0.001 | 0.56 (0.42–0.75) | <0.001 | 0.54 (0.44–0.66) | <0.001 |
  Model 3 | 0.66 (0.49–0.90) | 0.009 | 0.60 (0.39–0.91) | 0.015 | 0.66 (0.49–0.90) | <0.001 |
MSP | ||||||
  Model 1 | 1.58 (1.08–2.33) | 0.019 | 1.17 (0.82–1.52) | 0.484 | 1.28 (1.01–1.61) | 0.039 |
  Model 2 | 1.54 (1.04–2.27) | 0.031 | 1.18 (0.86–1.62) | 0.315 | 1.29 (1.02–1.63) | 0.034 |
  Model 3 | 2.02 (0.81–5.06) | 0.132 | 1.20 (0.76–1.89) | 0.434 | 1.33 (0.92–1.91) | 0.130 |
CRP | ||||||
  Model 1 | 2.56 (1.95–3.38) | <0.001 | 5.08 (3.27–7.89) | <0.001 | 3.29 (2.60–4.17) | <0.001 |
  Model 2 | 2.56 (1.94–3.39) | <0.001 | 5.17 (3.28–8.14) | <0.001 | 3.29 (2.60–4.18) | <0.001 |
  Model 3 | 2.54 (1.39–4.66) | 0.003 | 3.08 (1.87–5.09) | <0.001 | 2.67 (1.88–3.79) | <0.001 |